Physician profile
Robert S Venick
NPI 1235166075
$77,706.76
in general payments reported to CMS, 2019-2025
12 companies · $4,840 in 2025
The $4,840 reported for 2025 was more than what 90% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,637 · 2021: $4,800 · 2022: $2,169 · 2023: $22K · 2024: $38K · 2025: $4,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Travel and Lodging: $4,683 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,320 · Food and Beverage: $2,506 · Education: $4.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $53,587.50 |
| Travel and Lodging | $4,682.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,320.00 |
| Food and Beverage | $2,506.38 |
| Education | $4.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $55,887.34 | 2022-2025 | Livmarli |
| Vectivbio Ag | $6,763.10 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,679.08 | 2021-2022 | |
| Shire North American Group INC | $4,213.00 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $3,320.00 | 2024 | Bylvay |
| Fresenius Kabi USA, LLC | $1,688.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $700.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.75 | 2021 | |
| Mallinckrodt Hospital Products INC. | $109.13 | 2021 | |
| Gilead Sciences, INC. | $99.29 | 2022 | |
| Travere Therapeutics, INC. | $55.09 | 2019-2023 | Cholbam |
| Ironwood Pharmaceuticals, INC | $51.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Venick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.